BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32160292)

  • 21. IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome.
    Cogliatti SB; Bertoni F; Zimmermann DR; Henz S; Diss TC; Ghielmini M; Schmid U
    J Pathol; 2005 Jul; 206(3):320-7. PubMed ID: 15887292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
    Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C; Yao Y; Nastoupil L; Westin J; Fayad L; Nair R; Steiner R; Ahmed S; Samaniego F; Iyer SP; Oriabure O; Chen W; Song X; Zhang J; Badillo M; Moghrabi O; Aranda J; Tang G; Yin CC; Patel K; Medeiros LJ; Li S; Vega F; Thirumurthi S; Xu G; Neelapu S; Flowers CR; Romaguera J; Fowler N; Wang L; Wang ML; Jain P
    Am J Hematol; 2020 Jun; 95(6):623-629. PubMed ID: 32239765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
    Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
    Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clonal heterogeneity of mantle cell lymphoma revealed by array comparative genomic hybridization.
    Liu F; Yoshida N; Suguro M; Kato H; Karube K; Arita K; Yamamoto K; Tsuzuki S; Oshima K; Seto M
    Eur J Haematol; 2013 Jan; 90(1):51-8. PubMed ID: 23110670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.
    Panero J; Alves-Paiva RM; Roisman A; Santana-Lemos BA; Falcão RP; Oliveira G; Martins D; Stanganelli C; Slavutsky I; Calado RT
    Am J Hematol; 2016 May; 91(5):481-5. PubMed ID: 26852175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
    Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
    Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome.
    Rubio-Moscardo F; Climent J; Siebert R; Piris MA; Martín-Subero JI; Nieländer I; Garcia-Conde J; Dyer MJ; Terol MJ; Pinkel D; Martinez-Climent JA
    Blood; 2005 Jun; 105(11):4445-54. PubMed ID: 15718413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma.
    Wang L; Mo S; Li X; He Y; Yang J
    Cancer Biol Med; 2020 Aug; 17(3):726-739. PubMed ID: 32944402
    [No Abstract]   [Full Text] [Related]  

  • 29. Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop.
    Kahl BS; Gordon LI; Dreyling M; Gascoyne RD; Sotomayor EM
    Leuk Lymphoma; 2015; 56(9):2505-11. PubMed ID: 25944379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Familial lymphoid neoplasms in patients with mantle cell lymphoma.
    Tort F; Camacho E; Bosch F; Harris NL; Montserrat E; Campo E
    Haematologica; 2004 Mar; 89(3):314-9. PubMed ID: 15020270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells.
    Zhang J; Jima D; Moffitt AB; Liu Q; Czader M; Hsi ED; Fedoriw Y; Dunphy CH; Richards KL; Gill JI; Sun Z; Love C; Scotland P; Lock E; Levy S; Hsu DS; Dunson D; Dave SS
    Blood; 2014 May; 123(19):2988-96. PubMed ID: 24682267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PAX5 aberrant expression incorporated in MIPI-SP risk scoring system exhibits additive value in mantle cell lymphoma.
    Zhang X; Han Y; Nie Y; Jiang Y; Sui X; Ge X; Liu F; Zhang Y; Wang X
    J Mol Med (Berl); 2023 May; 101(5):595-606. PubMed ID: 37126184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene mutations and actionable genetic lesions in mantle cell lymphoma.
    Ahmed M; Zhang L; Nomie K; Lam L; Wang M
    Oncotarget; 2016 Sep; 7(36):58638-58648. PubMed ID: 27449094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel agents for mantle cell lymphoma: molecular rational and clinical data.
    Sarkozy C; Ribrag V
    Expert Opin Investig Drugs; 2020 Jun; 29(6):555-566. PubMed ID: 32321318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.
    Rodrigues JM; Porwit A; Hassan M; Ek S; Jerkeman M
    Leuk Lymphoma; 2021 Nov; 62(11):2637-2647. PubMed ID: 34080947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma.
    Islam TC; Asplund AC; Lindvall JM; Nygren L; Liden J; Kimby E; Christensson B; Smith CI; Sander B
    Leukemia; 2003 Sep; 17(9):1880-90. PubMed ID: 12970790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.
    Silkenstedt E; Arenas F; Colom-Sanmartí B; Xargay-Torrent S; Higashi M; Giró A; Rodriguez V; Fuentes P; Aulitzky WE; van der Kuip H; Beà S; Toribio ML; Campo E; López-Guerra M; Colomer D
    J Exp Clin Cancer Res; 2019 Nov; 38(1):446. PubMed ID: 31676012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. lncRNA FOXP4‑AS1 predicts poor prognosis and accelerates the progression of mantle cell lymphoma through the miR‑423‑5p/NACC1 pathway.
    Tao HF; Shen JX; Hou ZW; Chen SY; Su YZ; Fang JL
    Oncol Rep; 2021 Feb; 45(2):469-480. PubMed ID: 33416160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
    Hill HA; Qi X; Jain P; Nomie K; Wang Y; Zhou S; Wang ML
    Blood Adv; 2020 Jul; 4(13):2927-2938. PubMed ID: 32598477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Research advance of p53 gene in mantle cell lymphoma].
    Zhou LT; Zhu JB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):835-8. PubMed ID: 21729583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.